Invenra operates as a biotechnology company focused on early stage drug discovery.
Invenra is focused on discovering the next generation of best-in-class biologics, with an emphasis on antibodies and their derivatives. The company's proprietary technology combines the cell-free expression of full-length antibodies and extreme miniaturization, enabling the screening of unprecedented numbers of full-length antibodies in phenotypic assays. Invenra touts a broad scientific foundation and a team of scientists with deep expertise in key areas ranging from genomics to biochemistry to bioengineering. Their background is well balanced between cutting edge basic research and commercial products and services.The company was established in 2011 and is based in Madison, Wisconsin, United States.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Oct 3, 2017 | Series Unknown | $2.93M | 1 | — | — | Detail |
Jul 20, 2016 | Series Unknown | $3.01M | 1 | — | — | Detail |
May 24, 2016 | Series Unknown | $4.01M | 1 | — | — | Detail |
Feb 20, 2013 | Series Unknown | $3M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
NEW Capital Fund | — | Series Unknown |